CACS market seen reaching $6.37 billion by 2030

The cancer anorexia-cachexia syndrome market is projected to grow from $4.29 billion in 2026 to $6.37 billion by 2030, driven by rising cancer cases, higher healthcare spending and broader use of supportive oncology care. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Cancer anorexia-cachexia syndrome affects nutritional status, treatment tolerance and outcomes for cancer patients. - The market’s projected growth signals more spending on supportive oncology care, appetite stimulants, nutrition support and emerging cachexia therapies. - Rising cancer prevalence is increasing demand for management options that address weight loss and metabolic decline.

What happened: - The Business Research Company said the global cancer anorexia-cachexia syndrome market was valued at $3.88 billion in 2025 and is projected to reach $4.29 billion in 2026. - The market is forecast to grow to $6.37 billion by 2030. - The report pegs 2025-2026 growth at a 10.7% CAGR and 2026-2030 growth at a 10.4% CAGR. - The report was published Nov. 6, 2026. - More information is available in the full market report. - A free sample report is also available.

The details: - Cancer anorexia-cachexia syndrome is a complication in cancer patients marked by inflammatory responses, hormonal imbalances and altered nutrient metabolism. - The syndrome can worsen prognosis and increase resistance to cancer treatment. - The market’s recent expansion was linked to more advanced cancer cases, greater recognition of cachexia’s impact on treatment success, earlier use of appetite stimulants, hospital-based supportive care initiatives and more oncology nutrition research. - Future growth is expected to come from cachexia drug development, personalized supportive oncology care, more clinical trials, wider home-based cancer care and tighter integration of cachexia management into oncology protocols. - The report highlights targeted cachexia therapies, anti-inflammatory approaches, combination therapies, nutritional and metabolic support solutions and earlier intervention as key trends. - In August 2024, Macmillan Cancer Support said more than 3 million people in the UK were living with cancer, with that figure projected to hit 3.5 million by 2025, 4 million by 2030 and 5.3 million by 2040. - The UK Office for National Statistics said healthcare expenditure rose 5.6% in nominal terms from 2022 to 2023, after a 0.9% rise in 2022.

Between the lines: - The report points to a shift from symptom management toward earlier and more integrated cachexia care inside oncology treatment plans. - Faster growth in Asia-Pacific suggests demand is broadening beyond the largest current market in North America. - Higher healthcare spending may help absorb the cost of specialized treatments, nutrition interventions and palliative care tied to CACS management.

What's next: - The report expects more investment in cachexia drug development and clinical trials over the forecast period. - Broader use of home-based cancer care could expand access to supportive treatment models. - Ongoing growth in cancer incidence is likely to keep CACS on the agenda for oncology providers and drug developers.

The bottom line: - CACS is moving from a niche supportive-care issue to a larger oncology market backed by rising cancer prevalence, higher healthcare spending and a growing pipeline of treatment approaches.